Photo from archive.org
The PD-1 inhibitor pembrolizumab poses no significant risks for patients with HIV and cancer, according to data presented at a recent meeting of the Society for Immunotherapy of Cancer. The… Click to show full abstract
The PD-1 inhibitor pembrolizumab poses no significant risks for patients with HIV and cancer, according to data presented at a recent meeting of the Society for Immunotherapy of Cancer. The findings suggest that patients with HIV should no longer be excluded from clinical trials testing checkpoint inhibitors and other novel therapies for cancer.
Keywords:
cancer;
therapy hiv;
anti therapy
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!